|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 New York Avenue, NW |
Address2 | 8th Floor |
| City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103321-303
|
||||||||
|
6. House ID# 426590030
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Beth Anne Cole |
Date | 10/19/2026 10:00:22 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Direct to Consumer Advertising.
340B Drug Discount Program - Program Implementation & Oversight.
Accelerated Approval.
Breast Cancer Research.
Supply Chain Integrity and Traceability.
PBM Reform.
Coverage of Accelerated Approval Products.
Drug Benefit Design.
Orphan Drug Issues.
S. 1682/H.R.946: ORPHAN Cures Act.
Reimbursement and Coverage of Innovative Products.
Lower Costs, More Transparency Act.
Lower Costs, More Cures Act.
Patient Cost-Sharing.
Step Therapy.
Value-based Contracting and Communications.
User fee policy issues.
Pharmacy Benefit Manager reform and policy issues.
Drug cost and pricing policy issues.
Drug importation policy issues.
Competition policy issues.
Drug shortages policy issues.
IRA price negotiation expansion policy issues.
Rare Pediatric Disease Priority Review Voucher program policies.
SUSTAIN RFI/discussion draft.
Most Favored Nation (MFN) policy.
Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients.
Utilization management policies.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Edattel |
|
Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
|
Daniel |
Todd |
|
Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
|
Nicholas |
Uehlecke |
|
Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee |
|
Eric |
Bergren |
|
Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker |
|
Nick |
Magallanes |
|
Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novaitis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Part B.
GENErating cost Reductions for U.S. Medicaid (GENEROUS) model.
Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule.
Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule.
Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues.
H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025.
Part D redesign and policy issues including non-interference and rebates policy issues.
Part B policy issues.
Drug cost and pricing policy issues.
Medicare rebate policy issues.
CMS IPAY Guidance on the Medicare Drug Price Negotiation Program.
Medicaid rebate policy issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Edattel |
|
|
|
Daniel |
Todd |
|
|
|
Nicholas |
Uehlecke |
|
|
|
Eric |
Bergren |
|
|
|
Nick |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novaitis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Outbound investment issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eric |
Bergren |
|
|
|
Paul |
Edattel |
|
|
|
Daniel |
Todd |
|
|
|
Nicholas |
Uehlecke |
|
|
|
Nick |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novaitis AG, as its parent, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |